VTGN
Income statement / Annual
Last year (2025), VistaGen Therapeutics, Inc.'s total revenue was $486.00 K,
a decrease of 54.32% from the previous year.
In 2025, VistaGen Therapeutics, Inc.'s net income was -$51.42 M.
See VistaGen Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
03/31/2025 |
03/31/2024 |
03/31/2023 |
03/31/2022 |
03/31/2021 |
03/31/2020 |
03/31/2019 |
03/31/2018 |
03/31/2017 |
03/31/2016 |
| Operating Revenue |
$486.00 K |
$1.06 M |
-$227.00 K |
$1.11 M |
$1.09 M |
$0.00 |
$0.00 |
$0.00 |
$1.25 M |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$103.10 K
|
$91.20 K
|
$80.70 K
|
$0.00
|
$53.50 K
|
| Gross Profit |
$486.00 K
|
$1.06 M
|
-$227.00 K
|
$1.11 M
|
$1.09 M
|
-$103.10 K
|
$0.00
|
$0.00
|
$1.25 M
|
$0.00
|
| Gross Profit Ratio |
1
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
1
|
0
|
| Research and Development Expenses |
$39.38 M
|
$20.02 M
|
$44.38 M
|
$35.41 M
|
$11.93 M
|
$13.33 M
|
$17.10 M
|
$7.76 M
|
$5.20 M
|
$3.93 M
|
| General & Administrative Expenses |
$17.08 M
|
$14.06 M
|
$14.66 M
|
$10.45 M
|
$7.10 M
|
$0.00
|
$7.43 M
|
$6.44 M
|
$5.87 M
|
$13.92 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$2.80 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$17.08 M
|
$14.06 M
|
$14.66 M
|
$13.25 M
|
$7.10 M
|
$6.55 M
|
$7.43 M
|
$6.44 M
|
$5.87 M
|
$13.92 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$232.00 K
|
-$400.00
|
$0.00
|
-$48.70 K
|
$0.00
|
$426.80 K
|
-$2.30 K
|
| Operating Expenses |
$56.46 M
|
$34.09 M
|
$59.04 M
|
$48.89 M
|
$19.02 M
|
$19.87 M
|
$24.53 M
|
$14.20 M
|
$11.50 M
|
$17.85 M
|
| Cost And Expenses |
$56.46 M
|
$34.09 M
|
$59.04 M
|
$48.89 M
|
$19.02 M
|
$19.97 M
|
$24.53 M
|
$14.20 M
|
$11.50 M
|
$17.85 M
|
| Interest Income |
$4.56 M
|
$3.35 M
|
$49.00 K
|
$20.00 K
|
$15.00 K
|
$45.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$23.00 K
|
$0.00
|
$13.00 K
|
$15.00 K
|
$8.00 K
|
$8.90 K
|
$5.00 K
|
$777.00 K
|
| Depreciation & Amortization |
$635.00 K
|
$568.00 K
|
$532.00 K
|
$711.10 K
|
$477.60 K
|
$103.10 K
|
$91.20 K
|
$80.70 K
|
$54.90 K
|
$53.50 K
|
| EBITDA |
-$55.34 M |
-$32.45 M |
-$58.74 M |
-$47.05 M |
-$17.44 M |
-$20.65 M |
-$24.47 M |
-$14.25 M |
-$9.77 M |
-$17.80 M |
| EBITDA Ratio |
-113.86
|
-30.5
|
258.75
|
-42.43
|
-16.01
|
0
|
0
|
0
|
-7.81
|
0
|
| Operating Income Ratio |
-115.17
|
-31.03
|
261.09
|
-43.09
|
-16.46
|
0
|
0
|
0
|
-8.2
|
0
|
| Total Other Income/Expenses Net |
$4.56 M
|
$3.66 M
|
$26.00 K
|
$19.90 K
|
$2.20 K
|
-$796.90 K
|
-$30.70 K
|
-$143.90 K
|
-$4.60 K
|
-$29.37 M
|
| Income Before Tax |
-$51.41 M
|
-$29.36 M
|
-$59.24 M
|
-$47.76 M
|
-$17.93 M
|
-$20.77 M
|
-$24.59 M
|
-$14.34 M
|
-$10.25 M
|
-$47.22 M
|
| Income Before Tax Ratio |
-105.78
|
-27.59
|
260.98
|
-43.07
|
-16.46
|
0
|
0
|
0
|
-8.2
|
0
|
| Income Tax Expense |
$7.00 K
|
$4.00 K
|
$6.00 K
|
$3.40 K
|
$2.60 K
|
$2.60 K
|
$2.60 K
|
$2.40 K
|
$2.40 K
|
$2.30 K
|
| Net Income |
-$51.42 M
|
-$29.36 M
|
-$59.25 M
|
-$47.76 M
|
-$17.93 M
|
-$20.77 M
|
-$24.59 M
|
-$14.35 M
|
-$10.26 M
|
-$47.22 M
|
| Net Income Ratio |
-105.8
|
-27.6
|
261
|
-43.07
|
-16.46
|
0
|
0
|
0
|
-8.2
|
0
|
| EPS |
-1.67 |
-1.52 |
-8.51 |
-7.38 |
-14.74 |
-14.21 |
-25.83 |
-30.98 |
-40.85 |
-801.28 |
| EPS Diluted |
-1.67 |
-1.52 |
-8.51 |
-7.38 |
-14.74 |
-14.21 |
-25.83 |
-30.98 |
-40.85 |
-801.27 |
| Weighted Average Shares Out |
$30.71 M
|
$19.35 M
|
$6.96 M
|
$6.60 M
|
$2.87 M
|
$1.46 M
|
$952.08 K
|
$463.00 K
|
$251.05 K
|
$58.93 K
|
| Weighted Average Shares Out Diluted |
$30.71 M
|
$19.35 M
|
$6.96 M
|
$6.60 M
|
$2.87 M
|
$1.46 M
|
$952.08 K
|
$463.00 K
|
$251.05 K
|
$58.93 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
